Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?

Autor: Lankester, A.C., Locatelli, F., Bader, P., Rettinger, E., Egeler, M., Katewa, S., Pulsipher, M.A., Nierkens, S., Schultz, K., Handgretinger, R., Grupp, S.A., Boelens, J.J., Bollard, C.M., Westhafen Intercontinental Grp
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Graft Rejection
Male
medicine.medical_treatment
Adoptive cellular therapy
Cell- and Tissue-Based Therapy
Graft vs Host Disease
Hematopoietic stem cell transplantation
Disease
Pediatrics
NATURAL-KILLER-CELLS
0302 clinical medicine
VERSUS-HOST-DISEASE
Medicine
Child
0303 health sciences
Hematology
Graft vs Tumor Effect
adoptive cellular therapy
chimeric antigen receptor
pediatrics
stem cell transplantation
Hematopoietic Stem Cell Transplantation
Stem cell transplantation
ALLOGENEIC-DENDRITIC CELLS
Allografts
CHIMERIC ANTIGEN RECEPTOR
3. Good health
surgical procedures
operative
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA
Child
Preschool
Hematologic Neoplasms
Lymphocyte Transfusion
Female
T-REGULATORY CELLS
medicine.medical_specialty
MINOR HISTOCOMPATIBILITY ANTIGENS
Adolescent
chemical and pharmacologic phenomena
MESENCHYMAL STROMAL CELLS
ACUTE MYELOID-LEUKEMIA
Donor lymphocyte infusion
03 medical and health sciences
Immune system
Internal medicine
Humans
Intensive care medicine
030304 developmental biology
ACUTE LYMPHOBLASTIC-LEUKEMIA
Transplantation
business.industry
Mesenchymal stem cell
Infant
BONE-MARROW-TRANSPLANTATION
Chimeric antigen receptor
Immunology
business
030215 immunology
Zdroj: Biology of Blood and Marrow Transplantation, 21(3), 402. Elsevier Inc.
Biology of Blood and Marrow Transplantation, 21(3), 402-411
ISSN: 1083-8791
Popis: Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I. (C) 2015 American Society for Blood and Marrow Transplantation.
Databáze: OpenAIRE
Externí odkaz: